H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The positive stance follows a meeting between the research firm and the company’s CEO, Srinivas Rao, at the 27th Annual Global Investment Conference.

H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Source:unsplash

The CEO reiterated the company’s leading position in the psychedelics segment, backed by positive clinical data and the scalability of the programs in the pipeline. Management is especially bullish about the BPL-003 (intranasal mebufotenin, also known as 5-MeO-DMT) program, which is seen as a lead value driver within the interventional psychiatry framework.

Growing interest in psychedelics for psychiatric applications positions Atai Life Sciences for long-term growth. AbbVie’s $1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ bretisilocin underscores the growing interest in psychedelic treatments.

Atai Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments that transform patient care. It is developing psychedelics, other hallucinogens, entactogens, and related drugs for the treatment of psychiatric conditions.

While we acknowledge the potential of Atai Life Sciences N.V. (NASDAQ:ATAI) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATAI and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Best AI Stocks to Buy Under $5 and 12 Best Beginner Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.